Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis

By Sebba Anthony I.   Bonnick Sydney Lou   Kagan Risa   Thompson Desmond E.   Skalky Carol S.   Chen Erluo   de Papp Anne E.    

Current Medical Research and Opinion, Vol. 20, Iss. 12, 2004-12 ,pp. : 2031-2041

Informa Healthcare

Access to resources Recommend Favorite

Ibandronate: once-monthly and intravenous dosing options for osteoporosis treatment

By Emkey Ronald  

Women's Health, Vol. 2, Iss. 3, 2006-05 ,pp. : 341-349

Future Medicine

Access to resources Recommend Favorite

Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study

By Racewicz Artur J.   Schofield Pamela J.   Cahall David L.   Cline Gary A.   Burgio David E.  

Current Medical Research and Opinion, Vol. 23, Iss. 12, 2007-12 ,pp. : 3079-3089

Informa Healthcare

Access to resources Recommend Favorite

Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study

By Miller Paul D.   Epstein Sol   Sedarati Farhad   Reginster Jean-Yves  

Current Medical Research and Opinion, Vol. 24, Iss. 1, 2008-01 ,pp. : 207-213

Informa Healthcare

Access to resources Recommend Favorite

Pathogenesis and Bisphosphonate Treatment of Skeletal Events and Bone Pain in Metastatic Cancer: Focus on Ibandronate

By  

Oncology Research and Treatment, Vol. 35, Iss. 6, 2012-05 ,pp. : 380-387

Karger

Access to resources Recommend Favorite